Sep 30

Artiva Biotherapeutics Demonstrates Its Commitment to Corporate Social Responsibility by Joining Pledge 1% Movement

As one of the first biotechs to join Pledge 1%, Artiva is forging a way to integrate philanthropy into a biotech company’s mission and culture

SAN DIEGO, September 30, 2021 – Artiva Biotherapeutics, Inc., (“Artiva”) announced today that it has joined Pledge 1%, a global movement that supports the integration of philanthropy into corporate culture by inspiring companies to donate 1% of product, equity, profit, or employee time to causes of their choice. Artiva is one of the first biotech companies to join the over 15,000 companies across 100 countries that have committed to philanthropic efforts through Pledge 1%.

Artiva is an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer. In addition to its efforts to develop innovative technologies designed to deliver safe and accessible therapies to cancer patients, by joining the Pledge 1%, Artiva is demonstrating its commitment to philanthropic leadership, particularly in the biotech sector.

“I am extremely proud that we have decided to join this movement,” stated Jennifer Bush, Artiva’s Chief Legal and People Officer. “Corporate social responsibility and philanthropy are integral to Artiva’s culture and our core values, and we hope to inspire other companies in the biotech industry to join the Pledge 1% movement.”

“Our team derives tremendous purpose from our mission to improve the quality of life of cancer patients and their families, and we are energized to do more,” stated Fred Aslan, M.D., Artiva’s President and CEO. “Thanks to the support of our board, we have an opportunity to help address some of the social unmet needs facing cancer patients today.”

“We are incredibly excited that Artiva has taken the pledge,” said Amy Lesnick, chief executive of Pledge 1%. “Artiva can play a pivotal role in building this movement and promoting a new normal in which all companies—including in the biotech sector—integrate giving back as a core value in their business.”

“We are delighted to confirm our commitment to corporate social responsibility through our participation in Pledge 1%,” added Brian Daniels, M.D., Chairman of Artiva.

About Pledge 1%

Pledge 1% is a global movement that inspires, educates, and empowers every entrepreneur, company, and employee to be a force for good. Over 15,000 members in 100 countries around the world have used Pledge 1%’s flexible framework to ignite billions of dollars and hundreds of thousands of volunteer hours in new philanthropy. To learn more about Pledge 1%, and how your company can get involved, visit

About Artiva Biotherapeutics

Artiva’s mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies that are safe and accessible to cancer patients. The company has entered into therapeutic NK cell collaborations and/or license agreements with Merck and with Affimed N.V. Artiva’s AlloNK™ platform incorporates cell expansion, activation, and engineering technology developed by the Company’s corporate partner, GC LabCell, a member of the GC family of companies, one of the Republic of Korea’s leading biopharmaceutical groups. Artiva is headquartered in San Diego.


Media: Jessica Yingling, Ph.D., Little Dog Communications Inc.,, +1.858.344.8091

Investors: Michael E. Faerm, Artiva Biotherapeutics, Inc.,


Recent Posts

Artiva Biotherapeutics Receives Immunology Innovation of the Year in the 2023 BioTech Breakthrough Awards Program

Artiva recognized for advancing AlloNK®, the first allogeneic, off-the-shelf NK cell therapy with an IND allowance for autoimmune disease AlloNK in combination with rituximab aims to be a safe and effective option for patients with lupus nephritis and has scalable potential for future applications in other autoimmune diseases San Diego, Calif., November 8, 2023 –...

Beyond Biotech Podcast: Natural Killer Cells

Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. was featured on the Beyond Biotech Podcast hosted by to discuss recent milestones including: Demonstrating the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials, and Receiving FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf...

Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis

This marks the first IND clearance for an allogeneic, off-the-shelf NK or CAR-T cell therapy candidate in autoimmune disease Artiva also announced the formation of an advisory board to provide expertise in advancing innovative cell therapies for lupus and other autoimmune diseases SAN DIEGO, August 16, 2023 — Artiva Biotherapeutics, Inc., a clinical stage company...